Hims & Hers Health Inc. Stock News

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced two new clinical experts will join its global medical leadership team, led by Global Chief Medical Officer Pat Carroll, MD. Kultar Garcha, MD, will serve as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as ...

Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers.

SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becom...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, m...

Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as ​it continues to expand its international business.

SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- On July 29, 2026, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC sued the company over alleged improper business practices. The events have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Hims & Hers might have engaged in unlawf...